Bio-Works receives an additional order worth SEK 2.9 million for WorkBeads

Bio-Works has received another order from a production customer in the Netherlands who placed two orders earlier this year. The latest order is worth SEK 2.9 million. The customer is a global manufacturer of active pharmaceutical ingredients (API) with approximately 1,800 employees.

"This is further evidence that Bio-Works’ production customers value our products and customer service very highly," said Jonathan Royce, CEO of Bio-Works. "Our continuous efforts to expand business with existing customers who have already approved Bio-Works as a supplier are bearing fruit. At the same time, we are working hard to acquire new customers in order to broaden our customer base for the future.”

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail:arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visitwww.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-07 16:11 CEST.